



Contents lists available at ScienceDirect

Allergology International

journal homepage: <http://www.elsevier.com/locate/alit>

Review article

Chronic spontaneous urticaria and the extrinsic coagulation system

Yuhki Yanase, Shunsuke Takahagi, Michihiro Hide*

Department of Dermatology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan

ARTICLE INFO

Article history:

Received 22 August 2017

Accepted 8 September 2017

Available online xxx

Keywords:

Chronic spontaneous urticaria (CSU)

Endothelial cells

Extrinsic coagulation pathway eosinophils

Histamine

Tissue factor (TF)

Abbreviations:

CSU, chronic spontaneous urticarial;
 TF, tissue factor; PAR, protease activated
 receptor; HUVEC, human umbilical vein
 endothelial cells; HMVEC, human dermal
 microvascular endothelial cells; TLR, Toll-
 like receptor; LPS, lipopolysaccharide

ABSTRACT

Chronic spontaneous urticaria (CSU) is a common skin disorder characterized by daily or almost daily recurring skin edema and flare with itch. Recently, the activation of the blood coagulation cascade has been suggested to be involved in CSU, but the trigger of the coagulation cascade remains unclear. In this article, we review recent understanding of the relationship between the pathogenesis of CSU and extrinsic coagulation reactions. In CSU, vascular endothelial cells and eosinophils may play a role as TF-expressing cells for activating the extrinsic coagulation pathway. Moreover, the expression of TF on endothelial cells is synergistically enhanced by the activation of Toll-like receptors and histamine H₁ receptors. The activated coagulation factors may induce plasma extravasation followed by degranulation of skin mast cells and edema formation recognized as wheal in CSU. Molecules involved in this cascade could be a target for new and more effective treatments of urticaria.

Copyright © 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Pathophysiology of CSU

Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), is a common skin disorder characterized by spontaneously appearing wheals with itch and pruritus anywhere on the body for 6 weeks or longer.^{1–4} The crucial role of histamine in CSU has been proven by local release of histamine, which appears to be released from tissue resident mast cells, into the tissue and/or vasculature, and by the clinical efficiency of histamine H₁-receptor antagonists (antihistamines) in patients with urticaria.^{5,6} However, the mechanism of mast cell activation in CSU remains largely unclear. The presence of histamine releasing autoantibodies against IgE or the high affinity receptor (FcεRI) on mast cells and basophils may be detected in 30–50% of patients with CSU.^{7,8} The involvement of autoantigens has been suggested in view of the rapid effect of omalizumab, an anti-FcεRI monoclonal antibody. However, the continuous presence of autoantibodies and/or

autoantigens cannot explain diurnal and local occurrence of wheals observed in CSU. On the other hand, it has been suggested that infections by microorganisms, such as bacteria and/or virus, may be complicated as an underlying cause in many cases of CSU.

Relationship between CSU and the coagulation pathway

The involvement of the coagulation cascade, especially by the extrinsic coagulation pathway, being triggered by the exposure of plasma to tissue factor (TF), also known as factor III, has been demonstrated in the pathogenesis of CSU by a number of observations.^{9–14} Several reports suggest that heparin, an anticoagulant which inhibits the activity of coagulation factors, can be effective in the treatment of CSU.^{15,16} Moreover, oral anticoagulant drugs, such as warfarin which blocks that activities of factors FVIIa, FXa, and FIIa, may improve clinical symptoms in a certain population of patients with CSU unresponsive to antihistamines.¹⁷ These reports imply that the extrinsic coagulation pathway is directly related to the pathogenesis of CSU. Recently, several groups have shown the increase of blood coagulation markers in patients with CSU.^{9–14} Asero and his group showed that in patients with CSU, plasma levels of prothrombin fragment 1 + 2 (PF₁₊₂), a polypeptide of about 34 kD, and D-dimer are higher than those in normal controls

* Corresponding author. Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.

E-mail address: ed1h-w1de-road@hiroshima-u.ac.jp (M. Hide).

Peer review under responsibility of Japanese Society of Allergology.

<https://doi.org/10.1016/j.alit.2017.09.003>

1323–8930/Copyright © 2017, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

and correlate with disease severities.^{9–11} PF₁₊₂ is generated from prothrombin together with thrombin. Once thrombin is produced, it acts on fibrinogen and generates fibrin, which is subsequently stabilized by factor FXIIa and finally degraded by the plasmin pathway (fibrinolysis). D-dimer is produced by the degradation of stabilized fibrin, whereas FDP is produced by fibrinolysis of either stabilized or non-stabilized fibrin. We previously showed the increase of both FDP and D-dimer in patients with CSU, but not in healthy individuals or in patients with inducible type of urticarial (IU), in correlation with disease severity.¹⁸ Moreover, Takeda *et al.* revealed the elevation of blood coagulation potential involving the intrinsic coagulation factors, which enhance the common pathway of coagulation consisting of FVII, FX, FII and fibrinogen.^{12,13}

Activation of extrinsic coagulation pathway by TF expressed on cells

Damage to blood vessel walls exposes TF-expressing cells from underlying cell layers to the bloodstream, initiating the extrinsic coagulation cascade with calcium ions.^{19,20} High TF expression is found in highly vascularized organs (cells) such as brain (e.g., astrocytes), placenta (e.g., trophoblasts), and lung (e.g., alveolar cells) followed by heart (e.g., cardiac myocytes, pericytes, fibroblasts), kidney, intestine, testes, and uterus (e.g., epithelial cells surrounding the organs). TF is comprised of three domains: an extracellular domain (aa 1–219), followed by a hydrophobic spanning domain (aa 220–242) and a cytoplasmic tail (aa 243–263).²¹ The extracellular region contains FVII/VIIa binding domains. The TF-triggered activation of the extrinsic coagulation pathway results in the generation of active serine proteases (coagulant mediators): FVIIa, FXa and thrombin (FIIa). FIIa finally converts fibrinogen to fibrin, leading to fibrin deposition and the activation of platelets to form blood clots. These factors then mediate diverse intracellular activation and production of pro-inflammatory mediators including cytokines, adhesion molecules, and growth factors through protease activated receptors (PAR-1/2/3/4) present on the surface of several cell types.^{21,22} FVIIa activates target cells via PAR-2. FXa and FIIa activate various types of cells via PAR-1, 2, 3 and PAR-1, 3, 4, respectively. Fibrin is also able to promote an inflammatory response via Toll-like receptor (TLR)-4 (Fig. 1). Emerging evidence has revealed the

involvement of TF in wound repair, embryonic development, angiogenesis, tumor metastasis, cell adhesion/migration, innate immunity and many pathological conditions.

TF expression on eosinophils

In physiological conditions, TF is abundantly expressed in extravascular tissues, but is scarce on the cells exposed to blood circulation. Monocyte, granulocytes, and vascular endothelial cells may express TF on their cell surfaces in contact with the bloodstream, when exposed to bacteria, viruses, and cytokines, such as TNF α , IL-2 and IL-1 β in the blood. Recently, Moosbauer *et al.* found activated eosinophils as a major intravascular storage of TF.²³ Their *in vitro* experiments revealed that the expression of TF by eosinophils was enhanced by several cytokines, such as PAF and GM-CSF.²³ Moreover, Asero *et al.* showed a massive expression of TF by eosinophils in the lesional skin tissue of patients with CSU.²⁴ Furthermore, eosinophils are activated by autoantibodies against the low-affinity IgE receptor (Fc ϵ RII), which are detected in about 70% of CSU patients.²⁵ These reports support the involvement of TF-expressing eosinophils in the skin with the pathogenesis of CSU.

TF expression on vascular endothelial cells

To date, several reports have shown that histamine and LPS, an endotoxin found in the outer membrane of Gram-negative bacteria such as *Helicobacter pylori* and *Yersinia*, independently induced TF expression on vascular endothelial cells, suggesting that TF expressed on endothelial cells may activate the extrinsic coagulation pathway in blood vessels.²⁶ Nevertheless, the concentration of histamine (1110 ng/ml, equal to 10 μ M) required for significant expression of TF on endothelial cells, is much higher than that observed in sera of patients with CSU (<10 ng/ml),²⁷ and is even higher than that detected in patients with anaphylactic reactions (<100 ng/ml). Moreover, systemic symptoms such as high fever and large increases of C-reactive protein, known as LPS-induced symptoms, are not observed in most patients with CSU.²⁸ Thus, neither histamine nor LPS seem sufficient to induce the expression of TF triggering the coagulation pathway in patients with CSU. We recently reported that histamine, released from basophils, and LPS synergistically express TF on the surface of vascular endothelial cells, such as human umbilical vein endothelial cells (HUVECs) and human dermal microvascular endothelial cells (HMEVCs).²⁹ Moreover, synergistically expressed TF could activate the extrinsic coagulation pathway. Furthermore, active coagulation factors, FXa and IIa, produced by the extrinsic coagulation pathway induced intracellular gap formation between endothelial cells via PAR-1. Fujii *et al.* reported that the activation of the coagulation/fibrinolysis cascade occurs extravascularly as demonstrated by abundant fibrinogen deposits in the dermis of biopsy specimens from urticaria.³⁰ Our results also imply that the production of activated coagulation factors, such as Xa and IIa, causes intercellular gaps between endothelial cells via PAR-1 and that leakage of plasma into extravascular tissues plays a more important role for edema formation in CSU rather than thrombosis in the vasculature. To explore a mechanism of making endothelial cells more sensitive to histamine, we pre-treated HUVECs with LPS, and revealed an increase of mRNA of H₁ receptors and the enhancement of TF expression in response to histamine. The results suggest that lengthy exposure of endothelial cells to LPS makes HUVECs more sensitive to histamine. Although, we could not detect histamine-induced increase of TLR-4 expression in HUVECs in our experimental conditions, Talreja *et al.* demonstrated that histamine induced TLR-2 and TLR-4 expression in HUVECs and enhanced the sensitivity of HUVECs to LPS.³¹ These results imply that histamine and LPS mutually enhance the




Fig. 1. TF-dependent coagulation pathway and target receptors of the active coagulation factors. Tissue Factor (TF) is able to bind in the presence of calcium to Factor VII (FVII). TF/FVII is activated by auto-cleavage to TF/FVIIa. TF/FVIIa then converts FX to FXa. FXa converts FII (prothrombin) to FIIa (thrombin), which converts fibrinogen to fibrin. D-dimer is produced from fibrin by plasmin. PARs are G-protein-coupled receptors (GPCRs), where PAR-1, 3, 4 transmits FIIa signaling, PAR-1, 2, 3 transmits FXa signaling, and PAR-2 transmits FVIIa signaling. Fibrin is also able to promote an inflammatory response via TLR-4.

expressions of TLR-4 and histamine H₁ receptors on endothelial cells, resulting in the enhancement of TF expression in response to those stimuli. Moreover, we clarified that TLR-3, -5, -6 agonists also synergistically enhanced the expression of TF in HUVECs in the presence of histamine. Thus, various infections of bacteria and/or virus with those agonists might be involved in the pathogenesis of CSU through the production of active extrinsic coagulation factors.

The role of basophils

The relationship between basophils and CSU has also been gaining increasing attention. In CSU, the histamine release activities of basophils in response to anti-IgE are decreased.³² Moreover, the number of basophils in peripheral blood is negatively correlated with urticarial activities.³² Furthermore, basophils migrate from blood into the skin during wheal formation and are suggested to contribute to the persistence of wheals.³³ Approximately up to 50% of patients with CSU have antibodies to the ϵ subunit of Fc ϵ RI and/or IgE, which activate basophils in the blood of patients.^{1,34} Since those antibodies do not induce anaphylactic shock or severe allergic reactions *in vivo*, basophils in CSU patients should be under mild activation and persistently release small amount of histamine and other chemical mediators, as well as cytokines. Moreover, we confirmed the expression of phosphatidylserine (PS) on basophils in response to anti-IgE (Yanase *et al.* unpublished observation). Since PS also plays an important role for the activation of the extrinsic blood coagulation pathway together with TF and Ca²⁺, the basophil itself could be a potent activator or enhancer for the extrinsic blood coagulation pathway.

Mechanism of TF-triggered mast cell activation and edema formation

Since mast cells store a larger amount of histamine than that in basophils, and are located in tissues, histamine release from mast cells is critical for the definitive edema formation. Recently, Bossi

et al. demonstrated that human plasma from patients with CSU, but not that from healthy donors, induces histamine release from the human mast cell lines, LAD2 and HMC-1.³⁵ Asero *et al.* demonstrated the presence of histamine releasing factors with a molecular weight lower than 30 kDa in patients with CSU.³⁶ Several groups reported that human skin mast cells express the PAR-2 receptor on the plasma membrane and are activated by PAR-2 agonists, such as trypsin and activating peptide.^{37,38} Moreover, Carvalho *et al.* reported that PAR-2 on human mast cells in lesional psoriatic skin is up-regulated as compared with non-lesional psoriatic skin.³⁹ Vliagoftis reported that thrombin activates PAR-1 of bone marrow derived mast cells (BMMCs), causing adhesion of BMMCs to fibronectin.⁴⁰ Therefore, TF-induced activation of the coagulation factors may activate mast cells and their degranulation by FVIIa, FXa and FIIa by themselves via PARs. Since mast cells express the C5a receptor, and C5a is generated by the thrombin-dependent pathway,^{41–43} the production of thrombin triggered by TF may also cause mast cell activation via C5a.^{40,44} Puccetti *et al.* also reported that activated eosinophils by autoantibody release a number of inflammatory mediators such as major basic protein (MBP), which can provoke mast cells degranulation.²²

Taken together, the mechanisms leading to the development of CSU might be explained by a model below. The first step is a priming of endothelial cells by infections of pathogens, such as gram-negative bacteria with LPS for the expression of TF. Most of the basophils in CSU are mildly activated in blood and persistently release small amounts of histamine. When a local concentration of TLR agonists and histamine reaches the threshold of vascular endothelial cells to induce the expression of TF required for the activation of the extrinsic coagulation pathway, FXa and thrombin in the blood near the activated endothelial cells increase vascular permeability, and expose mast cells in the vicinity of leakage points to plasma containing the activated coagulation factors and other histamine releasing factors able to activate mast cells, and recruit other immune cells in the lesion. On the other hand, eosinophils are activated by anti-Fc ϵ RII autoantibodies and cytokines, such as IL-5




Fig. 2. Summary of the TF-involved pathways suggested in the pathogenesis of CSU. TF expressed on endothelial cells and eosinophils activate the extrinsic coagulation pathway followed by leakage of plasma from blood vessel and mast cell activation.

and TNF- α and express TF, followed by thrombin production. MBP from eosinophils may contribute to mast cell degranulation. Thrombin also produces C5a, which selectively activates skin mast cells. The activated mast cells in the skin release a large amount of histamine which induces long and robust edema formation recognized as wheals (Fig. 2).

Conclusion

In this review, we have described the predictable roles of TF-expressing vascular endothelial cells and eosinophils in the pathogenesis of CSU. Extrinsic coagulation-related molecules, such as activated-coagulation factors and PARs could be new and effective therapeutic targets for patients with severe and refractory CSU.

Acknowledgments

We wish to thank to Dr. Faiz Kermani for his review of the manuscript. The Study was founded by grants to Y.Y. from SENSHIN Medical Research Foundation, GSK Japan Research Grant 2016 and Grant-in-Aid for Scientific Research (C).

This study received the 2015 JSA Best Presentation Award by the Japanese Society of Allergy.

Conflict of interest

MH has received research funding from Kyowa Hakko Kirin. The rest of the authors have no conflict of interest.

References

- Jain S. Pathogenesis of chronic urticaria: an overview. *Dermatol Res Pract* 2014;2014:674709.
- Plan AP, Greaves M. Pathogenesis of chronic urticaria. *Clin Exp Allergy* 2009;39:777–87.
- Maurer M, Church MK, Gonçalo M, Sussman G, Sánchez-Borges M. Management and treatment of chronic urticaria (CU). *J Eur Acad Dermatol Venereol* 2015;29:16–32.
- Termeer C, Staubach P, Kurzen H, Strömer K, Ostendorf R, Maurer M. Chronic spontaneous urticaria – a management pathway for patients with chronic spontaneous urticaria. *J Dtsch Dermatol Ges* 2015;13:419–28.
- Harvima IT, Levi-Schaffer F, Draber P, Friedman S, Polakovicova I, Gibbs BF, et al. Molecular targets on mast cells and basophils for novel therapies. *J Allergy Clin Immunol* 2014;134:530–44.
- Hide M, Hiragun M, Hiragun T. Diagnostic tests for urticaria. *Immunol Allergy Clin North Am* 2014;34:53–72.
- Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. *N Engl J Med* 1993;328:1599–604.
- Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Giménez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med* 2013;368:924–35.
- Asero R. Plasma D-dimer levels and clinical response to ciclosporin in severe chronic spontaneous urticaria. *J Allergy Clin Immunol* 2015;135:1401–3.
- Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. *Intern Emerg Med* 2010;5:97–101.
- Asero R, Tedeschi A, Coppola R, Griffini S, Paparella P, Riboldi P, et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. *J Allergy Clin Immunol* 2007;119:705–10.
- Sakurai Y, Morioka S, Takeda T, Takahagi S, Hide M, Shima M. Increased thrombin generation potential in patients with chronic spontaneous urticaria. *Allergol Int* 2015;64:96–8.
- Takeda T, Sakurai Y, Takahagi S, Kato J, Yoshida K, Yoshioka A, et al. Increase of coagulation potential in chronic spontaneous urticaria. *Allergy* 2011;66:428–33.
- Takahagi S, Shindo H, Watanabe M, Kameyoshi Y, Hide M. Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate. *Acta Derm Venereol* 2010;90:425–6.
- Meyer-De Schmid JJ, Neuman A. Treatment of chronic urticaria with heparin. *Bull Soc Fr Dermatol Syphiligr* 1952;59:286–7.
- Chua SL, Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. *Br J Dermatol* 2005;153:216–7.
- Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. *Clin Exp Allergy* 2000;30:1161–5.
- Takahagi S, Mihara S, Iwamoto K, Morioka S, Okabe T, Kameyoshi Y, et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. *Allergy* 2010;65:649–56.
- Mackman N. The many faces of tissue factor. *J Thromb Haemost* 2009;7:136–9.
- Daubie V, Pochet R, Houard S, Philippart P. Tissue factor: a mini-review. *J Tissue Eng Regen Med* 2007;1:161–9.
- Chu AJ. Tissue factor mediates inflammation. *Arch Biochem Biophys* 2005;440:123–32.
- Chu AJ. Tissue factor, blood coagulation, and beyond: an overview. *Int J Inflamm* 2011;2011:367284.
- Moosbauer C, Morgenstern E, Cuvelier SL, Manukyan D, Bidzhekov K, Albrecht S, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. *Blood* 2007;109:995–1002.
- Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of tissue factor by eosinophils in patients with chronic urticaria. *Int Arch Allergy Immunol* 2009;148:170–4.
- Puccetti A, Bason C, Simeoni S, Millo E, Tinazzi E, Beri R, et al. In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. *Clin Exp Allergy* 2005;35:1599–607.
- Steffel J, Akhmedov A, Greutert H, Lüscher TF, Tanner FC. Histamine induces tissue factor expression: implications for acute coronary syndromes. *Circulation* 2005;112:341–9.
- Cho HJ, Cho SI, Kim HO, Park CW, Lee CH. Lack of association of plasma histamine with diamine oxidase in chronic idiopathic urticaria. *Ann Dermatol* 2013;25:189–95.
- Wedi B, Raap U, Kapp A. Chronic urticaria and infections. *Curr Opin Allergy Clin Immunol* 2004;4:387–96.
- Yanase Y, Morioka S, Iwamoto K, Takahagi S, Uchida K, Kawaguchi T, et al. Histamine and TLR ligands synergistically induce endothelial-cell gap-formation by the extrinsic coagulating pathway. *J Allergy Clin Immunol* 2017. <https://doi.org/10.1016/j.jaci.2017.07.026>.
- Fujii K, Usuki A, Kan-No Y, Ohgou N. Elevation of circulating thrombin-antithrombin III complex and fibrin degradation products in urticaria: a laboratory finding unrelated to intravascular coagulopathy. *J Dermatol* 2008;35:308–10.
- Talreja J, Kabir MH, Filla MB, Stechschulte DJ, Dileepan KN. Histamine induces Toll-like receptor 2 and 4 expression in endothelial cells and enhances sensitivity to Gram-positive and Gram-negative bacterial cell wall components. *Immunology* 2004;113:224–33.
- Grattan CE. Basophils in chronic urticaria. *J Invest Dermatol Symp Proc* 2001;6:139–40.
- Ito Y, Satoh T, Takayama K, Miyagishi C, Walls AF, Yokozeki H. Basophil recruitment and activation in inflammatory skin diseases. *Allergy* 2011;66:1107–13.
- Vonakis BM, Saini SS. New concepts in chronic urticaria. *Curr Opin Immunol* 2008;20:709–16.
- Bossi F, Frossi B, Radillo O, Cugno M, Tedeschi A, Riboldi P, et al. Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. *Allergy* 2011;66:1538–45.
- Cugno M, Tedeschi A, Frossi B, Bossi F, Marzano AV, Asero R. Detection of low-molecular-weight mast cell-activating factors in serum from patients with chronic spontaneous urticaria. *J Invest Allergol Clin Immunol* 2016;26:310–3.
- He SH, Xie H, Fu YL. Activation of human tonsil and skin mast cells by agonists of proteinase activated receptor-2. *Acta Pharmacol Sin* 2005;26:568–74.
- Moormann C, Artuc M, Pohl E, Varga G, Buddenkotte J, Vergnolle N, et al. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. *J Invest Dermatol* 2006;126:746–55.
- Carvalho RF, Nilsson G, Harvima IT. Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation. *Exp Dermatol* 2010;19:117–22.
- Vliagoftis H. Thrombin induces mast cell adhesion to fibronectin: evidence for involvement of protease-activated receptor-1. *J Immunol* 2002;169:4551–8.
- Asero R, Riboldi P, Tedeschi A, Cugno M, Meroni P. Chronic urticaria: a disease at a crossroad between autoimmunity and coagulation. *Autoimmun Rev* 2007;7:71–6.
- Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. *Nat Med* 2006;12:682–7.
- Ali H. Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. *Immunol Lett* 2010;128:36–45.
- Razin E, Marx G. Thrombin-induced degranulation of cultured bone marrow-derived mast cells. *J Immunol* 1984;133:3282–5.